L-3-n-butylphthalide improves cognitive impairment of APP/PS1 mice by BDNF/TrkB/PI3K/AKT pathway

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 7, 2014, Pages 1706-1713

  Xiang, Jing ^a   Pan, Jie ^b   Chen, Fujun ^a   Zheng, Linlin ^a   Chen, Yue ^a   Zhang, Shutao ^a   Feng, Wanyu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

APP PS1; BDNF TrkB PI3K AKT; L 3 n butylphthalide; Mice

Indexed keywords

EID: 84905638839     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Perry RJ, Watson P and Hodges JR. The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment. Neuropsychologia 2000; 38: 252-271.
2. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH and Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011; 7: 367-385.
3. Braak H and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
4. Braak H and Del Tredici K. Alzheimer's disease: intraneuronal alterations precede insoluble amyloid-beta formation. Neurobiol Aging 2004; 25: 713-718; discussion 743-716.
5. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H and Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404.
6. Auld DS, Kornecook TJ, Bastianetto S and Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to betaamyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002; 68: 209-245.
7. Schliebs R and Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 2006; 113: 1625-1644.
8. Coleman PD and Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 2003; 24: 1023-1027.
9. Okamura N, Suemoto T, Shiomitsu T, Suzuki M, Shimadzu H, Akatsu H, Yamamoto T, Arai H, Sasaki H, Yanai K, Staufenbiel M, Kudo Y and Sawada T. A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain. J Mol Neurosci 2004; 24: 247-255.
10. Muresan Z and Muresan V. Neuritic deposits of amyloid-beta peptide in a subpopulation of central nervous system-derived neuronal cells. Mol Cell Biol 2006; 26: 4982-4997.
11. Counts SE and Mufson EJ. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J Neuropathol Exp Neurol 2005; 64: 263-272.
12. Tapia-Arancibia L, Aliaga E, Silhol M and Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 2008; 59: 201-220.
13. Fumagalli F, Racagni G and Riva MA. The expanding role of BDNF: a therapeutic target for Alzheimer's disease? Pharmacogenomics J 2006; 6: 8-15.
14. Arancibia S, Silhol M, Mouliere F, Meffre J, Hollinger I, Maurice T and Tapia-Arancibia L. Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Dis 2008; 31: 316-326.
15. Murer MG, Yan Q and Raisman-Vozari R. Brainderived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2001; 63: 71-124.
16. Anderson AJ, Pike CJ and Cotman CW. Differential induction of immediate early gene proteins in cultured neurons by beta-amyloid (A beta): association of c-Jun with A beta-induced apoptosis. J Neurochem 1995; 65: 1487-1498.
17. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Ord T and Bredesen DE. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993; 262: 1274-1277.
18. Shimizu S, Narita M and Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999; 399: 483-487.
19. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-1136.
20. Xu HL and Feng YP. Effects of 3-n-butylphthalide on production of vasoactive substances by cerebral and aortic endothelial cells. Zhongguo Yao Li Xue Bao 1999; 20: 929-933.
21. Peng Y, Zeng X, Feng Y and Wang X. Antiplatelet and antithrombotic activity of L-3-n-butylphthalide in rats. J Cardiovasc Pharmacol 2004; 43: 876-881.
22. Huang JZ, Chen YZ, Su M, Zheng HF, Yang YP, Chen J and Liu CF. dl-3-n-Butylphthalide prevents oxidative damage and reduces mitochondrial dysfunction in an MPP(+)-induced cellular model of Parkinson's disease. Neurosci Lett 2010; 475: 89-94.
23. Xiong N, Huang J, Chen C, Zhao Y, Zhang Z, Jia M, Zhang Z, Hou L, Yang H, Cao X, Liang Z, Zhang Y, Sun S, Lin Z and Wang T. Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson's disease. Neurobiol Aging 2012; 33: 1777-1791.
24. Chang Q and Wang XL. Effects of chiral 3-nbutylphthalide on apoptosis induced by transient focal cerebral ischemia in rats. Acta Pharmacol Sin 2003; 24: 796-804.
25. Peng Y, Hu Y, Xu S, Li P, Li J, Lu L, Yang H, Feng N, Wang L and Wang X. L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AbetaPP/PS1-Alzheimer's transgenic mice. J Alzheimers Dis 2012; 29: 379-391.
26. Xu HL and Feng YP. Inhibitory effects of chiral 3-n-butylphthalide on inflammation following focal ischemic brain injury in rats. Acta Pharmacol Sin 2000; 21: 433-438.
27. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47-60.
28. Sun H, Zhang J, Zhang L, Liu H, Zhu H and Yang Y. Environmental enrichment influences BDNF and NR1 levels in the hippocampus and restores cognitive impairment in chronic cerebral hypoperfused rats. Curr Neurovasc Res 2010; 7: 268-280.
29. Yao ZH, Zhang JJ and Xie XF. Enriched environment prevents cognitive impairment and tau hyperphosphorylation after chronic cerebral hypoperfusion. Curr Neurovasc Res 2012; 9: 176-184.
30. Zheng P, Zhang J, Liu H, Xu X and Zhang X. Angelica injection reduces cognitive impairment during chronic cerebral hypoperfusion through brain-derived neurotrophic factor and nerve growth factor. Curr Neurovasc Res 2008; 5: 13-20.
31. Peng Y, Xing C, Lemere CA, Chen G, Wang L, Feng Y and Wang X. l-3-n-Butylphthalide ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells. Neurosci Lett 2008; 434: 224-229.
32. Peng Y, Xu S, Chen G, Wang L, Feng Y and Wang X. l-3-n-Butylphthalide improves cognitive impairment induced by chronic cerebral hypoperfusion in rats. J Pharmacol Exp Ther 2007; 321: 902-910.
33. Ma S, Xu S, Liu B, Li J, Feng N, Wang L and Wang X. Long-term treatment of l-3-n-butylphthalide attenuated neurodegenerative changes in aged rats. Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 565-574.
34. Schinder AF and Poo M. The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci 2000; 23: 639-645.
35. Mizuno M, Yamada K, Olariu A, Nawa H and Nabeshima T. Involvement of brain-derived neurotrophic factor in spatial memory formation and maintenance in a radial arm maze test in rats. J Neurosci 2000; 20: 7116-7121.
36. Minichiello L, Korte M, Wolfer D, Kuhn R, Unsicker K, Cestari V, Rossi-Arnaud C, Lipp HP, Bonhoeffer T and Klein R. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron 1999; 24: 401-414.
37. Oda T, Kume T, Izumi Y, Takada-Takatori Y, Niidome T and Akaike A. Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells. Eur J Pharmacol 2008; 598: 27-31.
38. Wakita S, Izumi Y, Nakai T, Adachi K, TakadaTakatori Y, Kume T and Akaike A. Staurosporine induces dopaminergic neurite outgrowth through AMP-activated protein kinase/mammalian target of rapamycin signaling pathway. Neuropharmacology 2014; 77: 39-48.
39. Dijkhuizen PA and Ghosh A. BDNF regulates primary dendrite formation in cortical neurons via the PI3-kinase and MAP kinase signaling pathways. J Neurobiol 2005; 62: 278-288.
40. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H and Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 2006; 51: 474-486.
41. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Niidome T, Sugimoto H, Fujii T, Okabe S and Akaike A. Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity. Eur J Pharmacol 2006; 549: 19-26.